Please login to the form below
short bowel syndrome
This page shows the latest short bowel syndrome news and features for those working in and with pharma, biotech and healthcare.
Pfizer buys dwarfism drug company Therachon for $810m
Will rival BioMarin pipeline drug. Pfizer is spending $340m to acquire Therachon, a European biotech with a drug in trials for achondroplasia, a form of short-limbed dwarfism. ... Therachon has another asset in development, a GLP-2 analogue called
Latest news
-
Alexion boosts rare disease portfolio with $8.4bn Synageva buy
2015. Synageva would also contribute a clinical development candidate called SBC-103 for mucopolysaccharidosis IIIb, known as Sanfilippo syndrome, which is in phase I/II trials. ... In recent weeks Shire agreed the takeover of NPS for $5.2bn, largely on
-
Relief for Shire as FDA clears NPS' Natpara
placebo. Natpara is NPS' second approved product after Gattex/Revestive (teduglutide), a GLP-2 analogue used for the long-term treatment of short bowel syndrome in adults that is expected to
-
Shire signs deal to buy NPS for $5.2bn
in the US for short bowel syndrome in 2012.
-
European drug applications 'stable but more complex in 2012'
is the first therapy to address the underlying mechanism of CF, and Takeda's Revestive (teduglutide) for treating adults with a rare but debilitating condition known as short bowel syndrome.
-
FDA clears six new drugs in time for the new year
Finally, the FDA issued an approval for the use of NPS Pharmaceuticals' Gattex (teduglutide) as a treatment for adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding.
More from news
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
The recent EMA approval of the subcutaneous formulation of its Inflammatory Bowel Disease (IBD) drug Entyvio was another milestone, as well as an important boost for patients. ... Projects that address gut inflammation beyond IBD are focused on coeliac
-
A rare talent
This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.
-
Deal Watch table for January 2015
NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel
-
Pharma deals during January 2015
Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and
-
Pharma deals during March 2013
NPS Pharmaceuticals acquired back from Takeda the rights outside North America to teduglutide, an orphan drug for adult short bowel syndrome and rPTH 1-84, which is approved for osteoporosis in ... 160. † Takeda Pharmaceuticals/ NPS Pharmaceuticals.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Therachon poaches Shire’s Aled Williams
There he was responsible for the commercialisation and development of Gattex/Revestive (teduglutide) for short bowel syndrome.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
